Dr. Cullis is an internationally recognized pioneer and leader in the field of lipids, biological membranes and liposomal drug delivery systems. His drug delivery systems have produced improved formulations of several cancer therapies as well as other drug agents. His lipid nanoparticles delivery system is a leading technology worldwide, enabling the therapeutic potential of siRNA. He has published over 300 scientific articles.
He has been very active in the development of several biotechnology companies and is recognized as a remarkable researcher and innovator. His work has led to three drugs that have been approved by regulatory agencies in the U.S. and Europe for the treatment of cancer and its complications and five more that have finished Phase I clinical studies. He has trained many graduate students and postdoctoral fellows, several of whom have gone on to distinguished careers in their own right.
Dr. Cullis co-founded The Canadian Liposome Company, Inex Pharmaceuticals (now Tekmira Pharmaceuticals), Northern Lipids Inc., Lipex Biomembranes Inc., and, most recently, Acuitas Pharmaceuticals, Precision NanoSystems and Mesentech Inc. In addition, he co-founded and was Scientific Director of the Centre for Drug Research and Development (CDRD) 2004-2010. He has been part of management teams that have raised over $200M in the biotechnology sector in BC. He is an inventor on over 40 patents.